Levi Alexander Garraway

Levi Alexander Garraway's AcademicInfluence.com Rankings

Medical

#1853

World Rank

#2231

Historical Rank

Pharmacology

#177

World Rank

#216

Historical Rank

medical Degrees

Levi Alexander Garraway

Philosophy

#5502

World Rank

#8323

Historical Rank

Logic

#2770

World Rank

#3807

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Levi Alexander Garraway's Degrees

Doctorate Medicine Harvard University

Why Is Levi Alexander Garraway Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Levi Alexander Garraway's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity (2012) (6062)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2008) (5775)
Comprehensive molecular profiling of lung adenocarcinoma (2014) (4095)
The landscape of somatic copy-number alteration across human cancers (2010) (3297)
Mutational heterogeneity in cancer and the search for new cancer-associated genes (2013) (2852)
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq (2016) (2825)
Mutational heterogeneity in cancer and the search for new cancer genes (2013) (2691)
Discovery and saturation analysis of cancer genes across 21 tumor types (2014) (2530)
Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (2458)
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma (2011) (2301)
A Landscape of Driver Mutations in Melanoma (2012) (2244)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade (2016) (2221)
Genomic Classification of Cutaneous Melanoma (2015) (2143)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden (2017) (2129)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma (2015) (2032)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) (2007)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing (2012) (1620)
Next-generation characterization of the Cancer Cell Line Encyclopedia (2019) (1561)
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma (2005) (1458)
Initial genome sequencing and analysis of multiple myeloma (2011) (1385)
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer (2012) (1367)
BRAF mutation predicts sensitivity to MEK inhibition (2006) (1323)
Defining a Cancer Dependency Map (2017) (1307)
The genomic complexity of primary human prostate cancer (2010) (1195)
Lessons from the Cancer Genome (2013) (1147)
Sequence analysis of mutations and translocations across breast cancer subtypes (2012) (1133)
Characterizing the cancer genome in lung adenocarcinoma (2007) (1122)
Punctuated Evolution of Prostate Cancer Genomes (2013) (1105)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. (2016) (1060)
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma (2007) (1052)
High-throughput oncogene mutation profiling in human cancer (2007) (1041)
Divergent clonal evolution of castration resistant neuroendocrine prostate cancer (2016) (1032)
Recurrent BRAF mutations in Langerhans cell histiocytosis. (2010) (948)
Highly Recurrent TERT Promoter Mutations in Human Melanoma (2013) (948)
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. (2011) (938)
COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation (2010) (778)
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. (2014) (769)
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. (2015) (727)
Melanoma genome sequencing reveals frequent PREX2 mutations (2012) (695)
Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy (2010) (653)
p63 is a prostate basal cell marker and is required for prostate development. (2000) (629)
MEK1 mutations confer resistance to MEK and B-RAF inhibition (2009) (616)
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis (2015) (616)
Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene (2007) (613)
An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules (2013) (533)
The long tail of oncogenic drivers in prostate cancer (2018) (529)
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. (2013) (515)
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. (2009) (510)
Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer (2013) (506)
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. (2009) (495)
Malignant melanoma: genetics and therapeutics in the genomic era. (2006) (493)
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer (2011) (491)
Melanoma: from mutations to medicine. (2012) (479)
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. (2012) (478)
An Integrated Approach to Uncover Drivers of Cancer (2010) (472)
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset (2011) (471)
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors (2017) (469)
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (445)
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples (2009) (439)
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. (2016) (436)
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. (2014) (430)
Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. (2015) (423)
Circumventing cancer drug resistance in the era of personalized medicine. (2012) (415)
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. (2014) (412)
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer (2011) (412)
Quantitative Proteomics of the Cancer Cell Line Encyclopedia (2020) (406)
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition (2013) (403)
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma (2016) (396)
Integrative Clinical Genomics of Advanced Prostate Cancer (2015) (383)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2019) (376)
RNF43 is frequently mutated in colorectal and endometrial cancers (2014) (371)
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing (2006) (354)
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma (2016) (353)
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. (2005) (341)
Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine (2014) (339)
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. (2018) (337)
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma (2014) (335)
Lineage dependency and lineage-survival oncogenes in human cancer (2006) (326)
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. (2013) (316)
ARID1B is a specific vulnerability in ARID1A-mutant cancers (2014) (312)
Genomics-driven oncology: framework for an emerging paradigm. (2013) (308)
Pharmacogenomic agreement between two cancer cell line data sets (2015) (306)
Genetic Mechanisms of Immune Evasion in Colorectal Cancer. (2018) (305)
Institutional implementation of clinical tumor profiling on an unselected cancer population. (2016) (303)
Precision oncology: an overview. (2013) (302)
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells (2016) (301)
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion (2011) (298)
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. (2012) (298)
Modeling genomic diversity and tumor dependency in malignant melanoma. (2008) (294)
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. (2018) (294)
Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. (2014) (289)
Integrative analysis of the melanoma transcriptome. (2010) (288)
The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts (2003) (278)
Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine (2013) (275)
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. (2009) (275)
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation (2009) (274)
The landscape of cancer cell line metabolism (2019) (273)
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma (2014) (269)
Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. (2010) (267)
Response and acquired resistance to everolimus in anaplastic thyroid cancer. (2014) (264)
Assessing the clinical utility of cancer genomic and proteomic data across tumor types (2014) (262)
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. (2014) (262)
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. (2012) (254)
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. (2015) (240)
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. (2015) (239)
Synthetic lethality as an engine for cancer drug target discovery (2019) (216)
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia (2013) (214)
Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location (2016) (211)
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. (2018) (209)
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition (2013) (207)
Evidence that the vectorial competence of phlebotomine sand flies for different species of Leishmania is controlled by structural polymorphisms in the surface lipophosphoglycan. (1994) (206)
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4 (2017) (202)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Clinical implications of the cancer genome. (2010) (195)
Functional genomics reveals serine synthesis is essential in PHGDH-amplified breast cancer (2011) (195)
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. (2016) (195)
Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts (2009) (189)
Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. (2016) (188)
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. (2007) (184)
Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer (2014) (184)
A single-cell landscape of high-grade serous ovarian cancer (2020) (184)
Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones. (1991) (177)
Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays (2006) (177)
Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state (2017) (173)
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines (2016) (172)
Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery (2010) (167)
A Convergence-Based Framework for Cancer Drug Resistance. (2018) (153)
A functional landscape of resistance to ALK inhibition in lung cancer. (2015) (151)
Nuclear factor I/B is an oncogene in small cell lung cancer. (2011) (147)
Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. (2016) (143)
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine (2016) (136)
Metabolomic adaptations and correlates of survival to immune checkpoint blockade (2019) (130)
IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment (2017) (129)
Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens (2013) (124)
AKT signaling in physiology and disease. (2010) (121)
gkmSVM: an R package for gapped-kmer SVM (2016) (120)
Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair (2013) (120)
Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (2018) (117)
Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors (2017) (117)
Isolation of virulence genes directing surface glycosyl-phosphatidylinositol synthesis by functional complementation of Leishmania. (1993) (116)
An oncogenic role for ETV1 in melanoma. (2010) (116)
A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (2020) (113)
Intermediate basal cells of the prostate: In vitro and in vivo characterization (2003) (113)
Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. (2016) (110)
Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. (2005) (107)
Erratum: Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma (Cell Reports (2016) 15(4) (857–865) (S2211124716303643) (10.1016/j.celrep.2016.03.075)) (2016) (106)
p85 Associates with Unphosphorylated PTEN and the PTEN-Associated Complex (2009) (102)
Oncologists' and Cancer Patients' Views on Whole-Exome Sequencing and Incidental Findings: Results from The CanSeq Study (2016) (101)
Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection (2014) (101)
Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants. (2016) (100)
Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium (2013) (99)
Attitudes of patients with cancer about personalized medicine and somatic genetic testing. (2012) (97)
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade (2018) (97)
Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation (2015) (97)
Unraveling the clonal hierarchy of somatic genomic aberrations (2014) (92)
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. (2017) (91)
Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set (2010) (90)
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. (2016) (90)
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer (2014) (90)
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. (2014) (87)
Characterizing genomic alterations in cancer by complementary functional associations (2016) (86)
Androgen-dependent regulation of Her-2/neu in prostate cancer cells. (2006) (86)
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer (2019) (85)
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer (2017) (84)
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. (2011) (83)
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder (2014) (81)
Epigenomic alterations in localized and advanced prostate cancer. (2013) (80)
Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. (2011) (79)
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance (2017) (77)
The SETDB1 histone methyltransferase is recurrently amplified in and accelerates melanoma (2011) (75)
Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors (2012) (74)
Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. (2013) (73)
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. (2014) (73)
Inherited DNA Repair Defects in Colorectal Cancer (2018) (73)
Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1 (2014) (72)
A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record (2013) (72)
TERT promoter mutations and monoallelic activation of TERT in cancer (2015) (72)
Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. (2016) (69)
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation (2015) (64)
SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines (2008) (64)
Rapid Intraoperative Molecular Characterization of Glioma. (2015) (64)
High‐throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide‐3‐kinase and other oncogenes (2012) (63)
Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. (2018) (62)
Oncogenic Activating Mutations Are Associated with Local Copy Gain (2009) (62)
A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas (2017) (60)
A 2‐Mb critical region implicated in the microcephaly associated with terminal 1q deletion syndrome (2007) (60)
The genomic landscape of prostate cancer (2012) (58)
Erratum: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing (2006) (58)
Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies (2016) (57)
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors (2015) (55)
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. (2020) (53)
TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas (2018) (51)
MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas. (2019) (50)
PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. (2015) (49)
Genetic modifiers of EGFR dependence in non-small cell lung cancer (2014) (48)
High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. (2012) (47)
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. (2015) (47)
22 The Cancer Cell Line Encyclopedia - Using Preclinical Models to Predict Anticancer Drug Sensitivity (2012) (46)
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers (2016) (44)
A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein (2014) (43)
Integrated genetic and pharmacologic interrogation of rare cancers (2016) (43)
Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study (2017) (42)
MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma (2012) (42)
Major copy proportion analysis of tumor samples using SNP arrays (2008) (42)
Sex differences in oncogenic mutational processes (2019) (41)
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. (2016) (39)
Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival (2020) (38)
Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses (2021) (37)
"Lineage addiction" in human cancer: lessons from integrated genomics. (2005) (36)
Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma (2016) (36)
Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. (2012) (36)
C-RAF mutations confer resistance to RAF inhibitors. (2013) (34)
PTR1-dependent synthesis of tetrahydrobiopterin contributes to oxidant susceptibility in the trypanosomatid protozoan parasite Leishmania major (2009) (33)
Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. (2017) (33)
Colorectal Cancers from Distinct Ancestral Populations Show Variations in BRAF Mutation Frequency (2013) (33)
Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy (2013) (32)
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. (2016) (31)
Frequent Mutation of the PI 3 K Pathway in Head and Neck Cancer Defi nes Predictive Biomarkers (2013) (29)
Applications of genomics in melanoma oncogene discovery. (2009) (29)
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). (2018) (28)
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. (2016) (27)
MDR1 inhibition: less resistance or less relevance? (2002) (27)
Characterizing reduced coverage regions through comparison of exome and genome sequencing data across ten centers (2017) (26)
From integrated genomics to tumor lineage dependency. (2006) (26)
Systematic genomic and translational efficiency studies of uveal melanoma (2017) (26)
Insertional mutagenesis by a modified in vitro Ty1 transposition system. (1997) (26)
Bidirectional cross talk between patient‐derived melanoma and cancer‐associated fibroblasts promotes invasion and proliferation (2016) (25)
A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. (2019) (25)
Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer (2016) (24)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer (2019) (20)
A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). (2013) (20)
Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with a KRAS Mutation or FGFR1 Gene Amplification (2012) (20)
Whole-genome sequencing and cancer therapy: is too much ever enough? (2012) (19)
Erratum: Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine (American Journal of Human Genetics (2016) 98(6) (1067–1076) (S0002929716301069) (10.1016/j.ajhg.2016.04.011)) (2016) (17)
A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine (2016) (17)
Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor. (2013) (16)
Identification of genes by functional complementation in protozoan parasite Leishmania (1994) (16)
The fuzzy world of precision medicine: deliberations of a precision medicine tumor board (2016) (15)
Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors (2015) (14)
Integrative Clinical Genomics of Advanced Prostate Cancer Graphical (2015) (14)
Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients. (2017) (14)
6-Phosphogluconate Dehydrogenase Links Cytosolic Carbohydrate Metabolism to Protein Secretion (2018) (13)
Lineage dependency and lineage-survival oncogenes in human cancer (2006) (13)
Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer (2017) (13)
Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience (2018) (13)
Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma (2019) (12)
CD38 in Advanced Prostate Cancers (2021) (12)
Concordance and discordance in tumor genomic profiling. (2012) (11)
Stepwise-edited, human melanoma models reveal mutations’ effect on tumor and microenvironment (2022) (11)
Isolation of virulence genes directing GPI synthesis by functional complementation of Leishmania. (1994) (10)
Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). (2018) (10)
An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. (2022) (10)
Array-based approaches to cancer genome analysis (2005) (9)
Abstract 3933: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling (2011) (9)
FGFR 3 expression in primary and metastatic urothelial carcinoma of the bladder (2014) (8)
An Oncogenic Role for ETV 1 in Melanoma (2010) (7)
Erratum: Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays (PLoS Computational Biology 2, 5, doi:10.1371/journal.pcbi.0020041) (2007) (7)
Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer (2007) (7)
Mechanisms of Resistance to Mitogen-Activated Protein Kinase Pathway Inhibition in BRAF-Mutant Melanoma. (2012) (7)
Prediction of drug response using genomic signatures from the Cancer Cell Line Encyclopedia (2010) (7)
Erratum: High-throughput oncogene mutation profiling in human cancer (Nature Genetics (2007) 39, (347-351)) (2007) (7)
Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. (2016) (7)
Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones (2012) (6)
PROFILE: Broadly based genomic testing for all patients at a major cancer center. (2013) (6)
Comprehensive molecular characterization of colorectal cancer reveals genomic predictors of immune cell infiltrates. (2015) (6)
Analysis of tumor mutation burden (TMB) in >51,000 clinical cancer patients to identify novel non-coding PMS2 promoter mutations associated with increased TMB. (2016) (6)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden (2017) (6)
Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes. (2013) (6)
BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. (2015) (6)
Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 (2015) (6)
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2020) (5)
Publisher Correction: The long tail of oncogenic drivers in prostate cancer (2019) (5)
Abstract 5455: Integrative analysis of the Cancer Cell Line Encyclopedia reveals genetic and transcriptional predictors of compound sensitivity (2011) (5)
Williams sneak attacks Instantaneous energetics of puma kills reveal advantage of felid (2014) (5)
Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. (2014) (5)
A Notch for noncoding RNA in melanoma. (2014) (5)
Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition. (2013) (4)
Molecular biology of cutaneous melanoma (2015) (4)
Erratum for the research article: Genomic proling of ER + breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance (Science Translational Medicine DOI: 10.1126/scitranslmed.aai7993) (2019) (4)
Increased Local Disorder of DNA Methylation Forms the Basis of High Intra-Leukemic Epigenetic Heterogeneity and Enhances CLL Evolution (2013) (4)
Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (4)
Defining a molecular subclass of treatment resistant prostate cancer. (2015) (4)
Abstract C72: Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors (2015) (4)
The genetic landscape of clinical resistance to RAF inhibition in melanoma. (2013) (4)
Abstract 3152: CanSeq: prospective clinical whole-exome sequencing of FFPE tumor samples. (2013) (3)
Abstract CN07-04: Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq (2015) (3)
A heuristic platform for clinical interpretation of cancer genome sequencing data. (2012) (3)
Making cancer research more inclusive (2021) (3)
Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (2018) (3)
Somatic alterations in the PTEN-PI3K-AKT-mTOR pathway in a cohort of 379 ovarian cancer patients. (2016) (3)
Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) (2020) (3)
Cell-free tumor DNA and TERT promoter mutations in bladder cancer. (2017) (2)
ERRATUM: Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium (2014) (2)
Distinct genetic profiles of extracranial and intracranial acral melanoma metastases (2016) (2)
Abstract PR10: A cyclic AMP-regulated melanocyte lineage program confers resistance to MAP kinase pathway inhibition (2013) (2)
Molecular Genetics of Melanocytic Neoplasia (2018) (2)
Abstract 4565: Whole exome sequencing links MAPK1 mutation to exquisite sensitivity to brief erlotinib monotherapy in head and neck cancer. (2013) (2)
Remember why we work on cancer (2017) (2)
Inferring Loss-of-Heterozygosity From Tumor-only Samples Using High-Density Oligonucleotide SNP Arrays (2)
Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer. (2016) (2)
Abstract 3576: Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load (2016) (2)
On or Off Target: Mutations, Models, and Predictions (2010) (2)
Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (2012) (2)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade. (2018) (1)
Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors (2015) (1)
Transgenerational genomic effect of chemotherapy exposure in testicular cancer survivors. (2015) (1)
Integrative analysis of the melanoma transcriptome Material Supplemental (2010) (1)
Abstract 5759: The landscape of copy-number changes across multiple human cancer types (2010) (1)
Abstract 3036: Real-time genomic characterization of metastatic pancreatic cancer to enable precision medicine (2017) (1)
Abstract 3037: Dissecting treatment resistance in patients with ovarian cancer and PDX-models using single-cell RNA-sequencing (2017) (1)
Polymorphism Array Analysis Human Lung Carcinomas Revealed by Single Nucleotide Homozygous Deletions and Chromosome Amplifications in (2005) (1)
Abstract PR02: Towards a Cancer Dependency Map (2017) (1)
Deliberations of a precision medicine tumor board. (2016) (1)
Enrichment of germline DNA-repair gene mutations in patients with colorectal cancer. (2017) (1)
Supplementary Material 10 (2014) (1)
Abstract 105: Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia (2010) (1)
Characterizing reduced coverage regions through comparison of exome and genome sequencing data across 10 centers (2017) (1)
Abstract PD6-3: Recurrent ESR1 fusion transcripts are associated with endocrine resistance in estrogen receptor positive, HER2 negative breast cancer (2015) (1)
Abstract B70: Conexic: A Bayesian framework to detect drivers and their function uncovers an endosomal signature in melanoma (2009) (1)
Unraveling the clonal hierarchy of somatic genomic aberrations (2014) (1)
Abstract P3-05-09: Exploring bazedoxifene and palbociclib as potential therapeutic strategies for overcoming ESR1-mediated endocrine resistance (2016) (1)
Abstract AP19: SINGLE–CELL RNA–SEQUENCING OF PATIENT–DERIVED OVARIAN CANCER CELLS AND PATIENT–DERIVED XENOGRAFT MODELS (2017) (1)
Highly multiplexed quantitative phosphosite assay for biology and preclinical studies (2020) (1)
Believe the miracles: of biomedical science and human suffering. (2016) (1)
Abstract NG04: Clinical acquired resistance to RAF inhibitor combinations in BRAF mutant colorectal cancer through MAPK pathway alterations (2015) (1)
Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC). (2015) (1)
Stepping on the GAS: a brake pedal for melanoma metastasis? (2009) (1)
Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453–456 (2013) (1)
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. (2022) (1)
The long tail of oncogenic drivers in prostate cancer (2018) (1)
Abstract P3-05-13: Estrogen-independent growth ofESR1-mutant breast cancer cells requires CDK4/6 (2016) (1)
Tumor genomic profiling of FFPE samples by massively parallel sequencing. (2011) (1)
Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (2020) (1)
A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer. (2016) (1)
Abstract 1806: TRIM24 is an oncogenic transcriptional activator in prostate cancer (2016) (1)
Abstract 4380: Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-sequencing (2016) (1)
Cancer patients' preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study. (2014) (1)
Abstract 3431: Functional characterization of ARID2 in melanoma and melanocytes (2014) (1)
Abstract 4017: Dissecting the clonal hierarchy of cancer-driving genomic lesions. (2013) (1)
The Genomic Architecture of Prostate Cancer (2014) (1)
The long tail of significantly mutated genes in prostate cancer. (2017) (1)
Inclusion of the ASH1 gene that governs the neuroendocrine differentiation of lung epithelium as an additional prototypic 'lineage-survival oncogene' (2007) (1)
Malignant Melanoma Modeling Genomic Diversity and Tumor Dependency in Updated (2008) (1)
Abstract 2570: An integrated germline analysis platform for comprehensive clinical cancer genomics. (2013) (1)
Abstract PD9-02: Evolutionary analysis of 462 serial metastatic biopsies from 208 patients with estrogen receptor-positive (ER+) metastatic breast cancer (MBC) using whole exome sequencing (WES) (2019) (1)
Abstract #3822: PDK1-SGK3 signaling in the absence of AKT activation in PIK3CA- mutant cancers (2009) (1)
Abstract 2011: The PI3K pathway is the most frequently mutated mitogenic pathway in HNSCC. (2013) (1)
Abstract 5221: Linking the molecular profile of colorectal tumors to germline genetic and environmental risk factors (2016) (1)
Abstract 2620: The Cancer Cell Line Encyclopedia project: From integrative cancer genomics to personalized cancer therapy (2010) (0)
Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER (2019) (0)
Abstract B33: Integration of genome-wide datasets identifies SOX10 as a lineage-specific genetic dependency in melanoma (2015) (0)
Abstract B44: Emerging targets from Cancer Dependency Map v0.1 (2017) (0)
Correction: Inferring Loss-of-Heterozygosity from Unpaired Tumors Using High-Density Oligonucleotide SNP Arrays (2007) (0)
SNP array based analyses of somatic genetic and the identification of MITF as a lineage survival oncogene amplified in malignant melanoma (0)
Abstract B108: A genome-scale shRNA synthetic lethal screen identifies enhancers of sensitivity to RAF inhibition. (2013) (0)
High-throughput oncogene mutation detection in human cancers by mass spectrometry-based genotyping (2006) (0)
Abstract PR02: Identification of ERK1/2 mutations that confer resistance to MAPK pathway inhibitors (2015) (0)
Title: Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer Authors: (2016) (0)
AKT-independent, PDK1-dependent signaling by oncogenic PIK3CA mutations (2008) (0)
Dooley 1 Nuclear Factor I / B is an Oncogene in Small Cell Lung Cancer (2011) (0)
Abstract B18: High-dimensional combinations of cancer drugs to induce synthetic lethality in colorectal cancer (2013) (0)
Abstract 3254: Dissecting genomic determinants of response to platinum-based chemotherapy in advanced NSCLC and colorectal cancer (2018) (0)
hi gh-t h roughput Detection of ac tionable Genomic al terations in cl inical t u mor s a mples by t a rgeted, Massively Parallel s e quencing (2012) (0)
Abstract B15: Comprehensive cistromic characterization of SOX10, a lineage-specific genetic dependency in melanoma, via the integration of functional genomic approaches (2017) (0)
A Functional Landscape o f Resistance to ALK Inhibition in Lung Cancer Graphical Abstract Highlights (2015) (0)
Abstract 95: Somatic mutations and copy number variations in cancer-associated genes in 695 ovarian cancer patients (2016) (0)
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors (2017) (0)
Abstract LB-113: MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability inBRAF,NRASandNF1-mutant melanomas (2019) (0)
Miniaturizing 3D assay for high-throughput drug and genetic screens for small patient-derived tumor samples (Conference Presentation) (2017) (0)
Abstract B39: Genomic copy number alterations introduce a gene-independent viability bias in CRISPR-Cas9 knock-out screens of cancer cell lines (2017) (0)
Abstract B17: Identification of Druggable Targets through Functional Multi-Omics in Renal Medullary Carcinoma (2017) (0)
Abstract LB-B04: Complex drug combinations can induce apoptotic killing in robust colorectal cancer cells (2015) (0)
Epigenomic Alterations in Localized and Advanced (2013) (0)
Phenotypic Characterizati on of a Comprehensive Set of MAPK 1 / ERK 2 Missense Mutants Graphical (2016) (0)
Opposing therapeutic efficacy of BET inhibitors is determined by cancer type-specific SPOP mutants (2016) (0)
Abstract LB-136: High concordance of whole-exome sequencing of cell-free DNA and matched biopsies enables genomic discovery in metastatic cancer (2016) (0)
the of cancer and proteomic data across tumor types. (2016) (0)
Abstract A02: Expanding tumor chemical-genetic interaction map using next-generation cancer models (2017) (0)
Supplemental Information Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia (2014) (0)
Publisher Correction: The long tail of oncogenic drivers in prostate cancer (2019) (0)
Abstract PR5: Identifying mechanisms of drug resistance to MAPK pathway inhibition via genome-scale rescue screens (2012) (0)
Abstract 571: Meta-analysis of genomic predictors of response to immune checkpoint therapy in metastatic melanoma (2017) (0)
Abstract 3925: Characterization of complex chromosomal aberrations in prostate cancer from whole genome sequencing (2011) (0)
Abstract 2953: Anticipating new biochemical mechanisms of resistance to Raf inhibition in Melanoma (2012) (0)
Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer (2014) (0)
From Genomic Diversity to Tumor Dependency in Human Cancer (2007) (0)
High Resolution SNP Arrays Identify Amplified Regions in Lung Cancer (2005) (0)
Abstract B27: Probing synthetic lethal interactions with RAF inhibition in BRAF-mutant colorectal cancer (2013) (0)
Abstract PR4: Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia (2010) (0)
Abstract C221: A genome-wide RNA interference screen identifies synthetic lethal interactions with the BRAF oncogene. (2013) (0)
Abstract LB-228: The identification of recurrent non-coding mutations in melanoma. (2013) (0)
Abstract 1564: A computational framework for removing mouse contamination in tumors sequenced from patient-derived xenografts (2017) (0)
Abstract 1311: High order drug combinations are required to effectively kill colorectal cancer cells (2016) (0)
Abstract 1010: Genomic analysis of recurrent ovarian cancer in patient-derived xenografts treated with platinum and taxane chemotherapy (2017) (0)
Abstract SY05-03: Dissecting genomic correlates of response and resistance to chemotherapy in bladder cancer through clinical computational oncology (2019) (0)
Inferring Loss-of-Heterozygosity from Tumors Without Paired Normals Using High-Density SNP Arrays (2005) (0)
Resource Integrative Clinical Genomics of Advanced Prostate Cancer (2016) (0)
Abstract 4819: Differential evolution of tumor heterogeneity in leiomyosarcomas and liposarcomas suggested by genomic profiling (2015) (0)
Abstract SY45-04: Development of therapeutic strategies by resolving the tumor ecosystem (2019) (0)
The landscape of cancer cell line metabolism (2019) (0)
1314 RECURRENT MUTATIONS IN SPOP DEFINE A DISTINCT MOLECULAR CLASS OF PROSTATE CANCER (2012) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
Abstract PR04: mTOR mutations in cancer (2015) (0)
Abstract 1286: Targeted deep sequencing of colorectal tumor tissues to study associations of tumor subtypes with germline genetic, lifestyle, and environmental risk factors (2017) (0)
Abstract B38: Developing a functional genomics platform to interrogate rare pediatric cancers (2016) (0)
Abstract 3931: Whole genome and whole exome sequencing of head and neck cancer (2011) (0)
Isolation ofvirulence genesdirecting surface glycosyl- phosphatidylinositol synthesis byfunctional complementation (1993) (0)
Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities. (2016) (0)
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2019) (0)
062 Human melanoma TILs share phenotypic and transcriptional properties with tissue resident memory T cells (2017) (0)
Abstract 136: Refining the molecular profile of colorectal tumors to expand prevention and treatment opportunities (2016) (0)
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2020) (0)
Next-generation characterization of the Cancer Cell Line Encyclopedia (2019) (0)
065 Highly conserved tissue immune signatures are co-opted in cancer (2017) (0)
Abstract PR01:Fusobacterium nucleatumand mutational landscape of colorectal cancer in whole-exome sequencing analysis (2017) (0)
The Genomic Landscape of Prostate Cancer this this you. Your (2012) (0)
Abstract 957: Towards precision functional genomics via next-generation functional mapping of cancer variants (2015) (0)
Abstract 923: Separating the wheat from the chaff: A first look at the Cancer Cell Lines Encyclopedia sequencing data (2011) (0)
Abstract 1953: Accelerating prediction of pediatric and rare cancer vulnerabilities using next-generation cancer models (2017) (0)
Spotlight on Clinical Response Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER þ Breast Cancers with a KRAS Mutation or FGFR 1 Gene Ampli fi cation (2012) (0)
Abstract 3111: The ETS factor ETV1 is an oncogene in melanoma (2010) (0)
Abstract 5647: Intron retention as a novel source of tumor neoantigens associated with response to checkpoint inhibitor therapy (2017) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
Abstract 1139: Complete characterization of prostate cancer genomes by massively parallel sequencing (2010) (0)
Abstract 1073: A systematic approach to identify the Ras-dependent C-RAF(Ser338)-phosphorylating kinase (2011) (0)
Abstract LB-249: Oncogene-mediated alterations in chromatin conformation (2011) (0)
Abstract SY17-02: A systems approach to understanding tumor specific drug response (2011) (0)
200 DEFINING THE MECHANISTIC BASIS OF SPOP MUTATIONS IN PROSTATE CANCER (2013) (0)
Abstract 5769: A novel, high-throughput approach to discovering drug-resistance genes identifies CRAF, CrkL, and TPL2/COT as drivers of resistance to BRAFV600E inhibition (2010) (0)
Somatic cancer mutations across populations (2007) (0)
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer (2017) (0)
Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC). (2016) (0)
Abstract 4601: Punctuated evolution of prostate cancer genomes. (2013) (0)
Synthetic lethality as an engine for cancer drug target discovery (2019) (0)
Abstract 5114: Integrative analysis of the Cancer Cell Line Encyclopedia reveals genetic and transcriptional predictors of compound sensitivity (2012) (0)
Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance (2019) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
Clinical actionability of germline testing in patients with limited colorectal polyps. (2017) (0)
Assigning clinical meaning to somatic and germline whole exome sequencing data to guide cancer precision medicine. (2016) (0)
Abstract PR01: Global chromatin profiling identifies NSD2 mutations in pediatric acute lymphoblastic leukemia (2013) (0)
Abstract C070: REAL variance in genomic testing by sex, age, race, ethnicity, and language: PROFILE database 7/2011 - 1/2022 (2023) (0)
Abstract LB-246: Recurrent inactivating mutations in SPOP define a molecular subset of prostate cancer (2011) (0)
S3-4: ER Downregulation with Fulvestrant in Combination with pan-PI3K Inhibitor BKM120 Synergizes Against ER+/PI3K-Mutant Breast Cancer Xenografts In Vivo. (2011) (0)
Rapid IntraoperativeMolecular Characterization of Glioma (2015) (0)
Abstract 819: Targeted sequencing to detect somatic mutations, translocations and copy-number variation in human tumors simultaneously. (2013) (0)
Correction: Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples (2009) (0)
Abstract IA13: Recurrent SPOP mutations define a distinct molecular subclass of prostate cancer (2012) (0)
Abstract 2371: Heterogeneity of resistance mechanisms in lung adenocarcinoma patients with acquired resistance to EGFR inhibitors (2014) (0)
Abstract 3566: The long tail of significantly mutated genes in prostate cancer (2017) (0)
Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014. (2015) (0)
Abstract PR05: Genome-scale CRISPR-Cas9 screening to identify essential genes and pathways in pancreatic cancer (2016) (0)
Abstract 2150: Alternative treatment strategies to overcome MAPK inhibitor resistance in melanoma (2016) (0)
Abstract A23: An integrated platform for the functional annotation of the cancer genome (2009) (0)
Abstract 5561: Single-cell analysis reveals an adaptive, transiently heritable, slowly-dividing, drug-resistant state inhibitable by drug combinations (2017) (0)
Theurillat in SPOP-mutant prostate cancer Ubiquitylome analysis identifies dysregulation of effector substrates (2014) (0)
Abstract 2930: Global chromatin profiling reveals NSD2 mutation in pediatric ALL (2014) (0)
Abstract 1724: Genomic mechanisms of exquisite sensitivity and acquired resistance to everolimus in a patient with anaplastic thyroid carcinoma (2014) (0)
Correction: Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples (2009) (0)
Abstract 3965: An algorithm to detect somatic mutations in cancer specimens using mass spectrometric genotyping (2012) (0)
Abstract 13: Chemical genomics identifies MCL1 repressors and resistance mechanism (2011) (0)
Label-free longitudinal monitoring of melanogenesis in the evolution of melanoma treatment resistance (Conference Presentation) (2017) (0)
Implementation of a prostate cancer‐specific targeted sequencing panel for credentialing of patient‐derived cell lines and genomic characterization of patient samples (2022) (0)
Abstract PR17: Single-cell analysis reveals an adaptive, slowly-dividing, de-differentiated, drug-resistant cell state selectively inhibitable by drug combinations (2017) (0)
Study of genetic alterations in soft tissue sarcomas by SNP arrays, expression profiling and high-throughput sequencing (2007) (0)
Abstract PL07-01: Molecular profiling of breast cancer in Mexico: Identification of novel therapeutic targets through whole genome sequencing analysis. (2012) (0)
Molecular determinants of resistance to CDK4/6 inhibition in ER+ breast cancer (2016) (0)
Abstract 4367: Accelerating prediction of tumor vulnerabilities using next-generation cancer models (2016) (0)
Abstract P3-06-11: Understanding resistance mechanisms of PIK3a inhibition in breast cancer (2016) (0)
Abstract PR07: Towards precision functional genomics via next-generation functional mapping of cancer variants (2015) (0)
Abstract B26: Accelerating prediction of tumor vulnerabilities using next-generation cancer models (2016) (0)
608 COMBINING DNA-SEQ AND RNA-SEQ FOR DISCOVERY OF NOVEL MUTATIONS IN HUMAN PROSTATE CANCER (2011) (0)
Whole‐exome sequencing analyses of colorectal cancer with Fusobacterium nucleatum (2017) (0)
Abstract MIP-075: SOMATIC MUTATIONS AND COPY-NUMBER VARIATIONS IN OVARIAN CANCERS VIA TARGETED SEQUENCING OF EXONS OF 300 CANCER-ASSOCIATED GENES, INCLUDING MULTIPLE DNA DAMAGE REPAIR GENES (2017) (0)
Novel driver genes and genomic predictors of immune infiltrates in colorectal cancer. (2016) (0)
Abstract B23: Genomic sequencing of metastatic hormone-receptor positive breast cancer implicates AKT1 in driving resistance to cyclin-dependent kinase 4/6 inhibitors (2020) (0)
Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations (2017) (0)
Abstract 3693: Small molecule microarray screens for inhibitors of oncogenic ETS factors (2010) (0)
Abstract LB-227: Truncal activating MAPK and PI3K pathway alterations and exceptional response to dual pathway inhibition in anaplastic thyroid cancer (2016) (0)
Supplementary Material 8 (2013) (0)
Abstract 1224: Deep targeted tumor sequencing of colorectal cancer cases to study associations of molecular subtypes with clinical, genetic, and lifestyle risk factors (2018) (0)
LG-47TYPE II RAF INHIBITORS INHIBIT BRAF MUTATIONS AND TRUNCATED FUSIONS IN PEDIATRIC LOW-GRADE GLIOMAS (2016) (0)
Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade (2020) (0)
Abstract A1-15: Systematic genomic characterization of uveal melanoma (2015) (0)
Abstract PR18: Somatic ERCC2 mutations, nucleotide excision repair (NER) function, and cisplatin response in muscle-invasive bladder cancer (MIBC) (2017) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
Abstract LB-122: High-throughput tumor genomic profiling by massively parallel sequencing (2010) (0)
037 A systems immunology approach to classify melanoma tumor infiltrating lymphocytes (TILs) informs and models overall survival (2022) (0)
Abstract LB-018: Defining a molecular subclass of treatment-resistant prostate cancer (2015) (0)
Abstract 237: Enrichment of AXL-high/ MITF-low melanoma cells in the presence of MAPK inhibitorsin vitro (2016) (0)
Abstract 4727: Genomic characterization of brain metastases reveals divergent evolution and metastasis specific mutations (2015) (0)
Abstract 3429: Synthetic lethal RNAi screens to nominate potential therapeutic combinations for uveal melanoma (2014) (0)
Implementation of single-cell genomics as a translational tool in patients with metastatic melanoma. (2016) (0)
Abstract B20: A genome-scale RNA interference screen for resistance mechanisms to BRAF inhibition in melanoma (2012) (0)
Abstract 600: Melanoma and ovarian cancer cells tested for drug sensitivity using anchorage-independent growth (2016) (0)
428 Clinical acquired resistance to combined RAF/EGFR or RAF/MEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterations (2014) (0)
Safety of bevacizumab in patients with glioblastoma multiforme ( GBM ) : a single institution ’ s experience (2011) (0)
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine (2016) (0)
Abstract 5056: A glimpse into the somatic mutation landscape of melanoma through exome sequencing of 121 tumor-normal pairs (2012) (0)
Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Levi Alexander Garraway?

Levi Alexander Garraway is affiliated with the following schools:

Massachusetts Institute of Technology
Harvard University

Levi Alexander Garraway's Academic­Influence.com Rankings

Levi Alexander Garraway's Degrees

Why Is Levi Alexander Garraway Influential?

Levi Alexander Garraway's Published Works

Published Works

What Schools Are Affiliated With Levi Alexander Garraway?

Levi Alexander Garraway's AcademicInfluence.com Rankings